Skip to main content
. 2022 Feb 21;23(4):2358. doi: 10.3390/ijms23042358

Table 2.

Candidates of molecular targeting drugs for vascular anomalies.

Diseases Target Drug
VEGF receptor Pazopanib
PROS PI3K Alpelisib
PROS Akt Miransertib
Venous malformation
Lymphatic malformation
mTOR Rapamycin
Arteriovenous malformation BRAF Vemurafenib
Arteriovenous malformation MEK Trametinib